Core Insights - Drug Pharmacokinetics and Pharmacodynamics (PKPD) is increasingly critical in drug discovery, prompting Viva Biotech to develop an integrated pharmacology platform that supports a wide range of drug modalities from in vitro ADME assays to in vivo PK and efficacy studies [1] Group 1: Pharmacology Platform - Viva Biotech's pharmacology platform encompasses various drug modalities, including small molecules, PROTACs, peptides, and antibodies, facilitating comprehensive drug development processes [1][6] - The platform employs a consistent analytical framework for evaluating pharmacokinetics across different modalities, enabling effective comparison and decision-making [2][3] Group 2: Antibody Programs - For antibody programs, Viva Biotech utilizes an engineered hFcRn/B2M–MDCK Transwell system to assess antibody transcytosis, which correlates strongly with clinical antibody half-life data, thus aiding in early candidate ranking [4] - The platform supports the evaluation of Fc-engineering variants and Fc fusion proteins, providing a cost- and time-efficient approach for in vitro PK screening [4] Group 3: Mechanistic Bioassays - The integration of DMPK decisions with mechanistic bioassays enhances the actionability of drug development, with Viva Biotech offering a portfolio that includes immune-cell activation assays and tumor efficacy evaluations [5] - In vivo capabilities include tumor efficacy assessments using various models, supporting comprehensive evaluations of exposure, target engagement, and functional outcomes [5] Group 4: Company Experience and Integration - With over a decade of experience in early drug discovery, Viva Biotech has strengthened its DMPK and pharmacology capabilities through facility expansion and integration with disease-focused studies across multiple therapeutic areas [6] - The company has established a comprehensive DMPK platform that connects structure-based discovery with various stages of drug development, supporting data-driven decisions throughout the preclinical phase [6]

Core Insights - Cyclic peptides are gaining prominence as a therapeutic innovation, bridging the gap between small molecules and large biologics, and are particularly suited for addressing traditionally "undruggable" targets [1][3] Industry Overview - Global investment in peptide pipelines is steadily increasing, highlighting the rising importance of cyclic peptides in drug discovery [1] - The ongoing webinar series on Medicinal Chemistry for Cyclic Peptide Drug Discovery indicates strong global interest in this area, showcasing the opportunities and challenges faced [2] Company Capabilities - Viva Biotech supports cyclic peptide discovery through in-house phage display and a DEL library, utilizing AI-based methods for structure prediction and design [4] - The company has established a comprehensive platform for peptide drug discovery, having delivered over 82,000 protein structures and synthesized more than 3,000 peptides, with over 80% being cyclic [8] Case Studies - Cyclosporine A demonstrates how a hydrophobic cyclic peptide can achieve oral exposure (~30%) and highlights the importance of structural studies in understanding its pharmacokinetics [5] - MK-0616 exemplifies a successful medicinal chemistry approach, achieving long half-lives (35–130 h) and significant reductions in PCSK9 and LDL-C levels through careful design and formulation [6][7] Future Directions - The integration of various methods and tools is crucial for practical cyclic peptide discovery at scale, with plans for continued collaboration with global partners to advance cyclic peptides as a therapeutic frontier [10]